scispace - formally typeset
R

Roland Moll

Researcher at University of Marburg

Publications -  128
Citations -  7400

Roland Moll is an academic researcher from University of Marburg. The author has contributed to research in topics: Sentinel node & Cytokeratin. The author has an hindex of 42, co-authored 128 publications receiving 6920 citations.

Papers
More filters
Journal ArticleDOI

The human keratins: biology and pathology

TL;DR: Since keratins also exhibit characteristic expression patterns in human tumors, several of them have great importance in immunohistochemical tumor diagnosis of carcinomas, in particular of unclear metastases and in precise classification and subtyping.
Journal ArticleDOI

Synaptophysin: a marker protein for neuroendocrine cells and neoplasms

TL;DR: The results show that synaptophysin, and the vesicles that contain it, can occur in normal and neoplastic neuroendocrine cells of neural type, as demonstrated by colocalization with neurofilaments, as well as in those of epithelial type, including cytokeratin filaments and desmoplakins.
Journal ArticleDOI

The ubiquitin-specific protease USP28 is required for MYC stability

TL;DR: The MYC proto-oncogene encodes a transcription factor that has been implicated in the genesis of many human tumours and one of these genes encodes USP28, an ubiquitin-specific protease required for MYC stability in human tumour cells.
Journal ArticleDOI

Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept

TL;DR: A previously unidentified cell population within the epithelial compartment of the breast, which displays the phenotypic characteristics of a committed stem cell, is visualized, which might serve as a tool to unravel the regulatory mechanisms that govern regeneration and abnormal proliferation of breast epithelium at the cellular level.
Journal ArticleDOI

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

TL;DR: Combination treatment was not superior to monotherapy concerning progression-free and long-term survival in patients with progressive metastatic neuroendocrine foregut and midgut tumors; patients responding to treatment and those with slow spontaneous tumor growth had a survival advantage.